Related resources
Full-text held externally
- PMID: 24996433
- UKPMCID: 24996433
- DOI: 10.1136/jclinpath-2014-202467
Search for item elsewhere
University researcher(s)
Academic department(s)
RAS testing of colorectal carcinoma-a guidance document from the Association of Clinical Pathologists Molecular Pathology and Diagnostics Group.
Wong, Newton Acs; Gonzalez, David; Salto-Tellez, Manuel; Butler, Rachel; Diaz-Cano, Salvador J; Ilyas, Mohammad; Newman, William; Shaw, Emily; Taniere, Philippe; Walsh, Shaun V
Journal of clinical pathology. 2014;.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 24996433
- UKPMCID: 24996433
- DOI: 10.1136/jclinpath-2014-202467
Abstract
Analysis of colorectal carcinoma (CRC) tissue for KRAS codon 12 or 13 mutations to guide use of anti-epidermal growth factor receptor (EGFR) therapy is now considered mandatory in the UK. The scope of this practice has been recently extended because of data indicating that NRAS mutations and additional KRAS mutations also predict for poor response to anti-EGFR therapy. The following document provides guidance on RAS (i.e., KRAS and NRAS) testing of CRC tissue in the setting of personalised medicine within the UK and particularly within the NHS. This guidance covers issues related to case selection, preanalytical aspects, analysis and interpretation of such RAS testing.